FilingSEC EDGAR8-K
aTyr Pharma Reaches FDA Alignment on Phase 3 Protocol for Efzofitimod
· SEC accepted
StagePhase 3 Preparation
Filing content
aTyr Pharma has reached alignment with the FDA on the Phase 3 study protocol for its lead candidate, efzofitimod, for pulmonary sarcoidosis, with activities expected to begin in Q4 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…